120 related articles for article (PubMed ID: 1742850)
1. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.
Eder JP; Elias AD; Ayash L; Wheeler CA; Shea TC; Schnipper LE; Frei E; Antman KH
Cancer Chemother Pharmacol; 1991; 29(1):61-5. PubMed ID: 1742850
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide with mesna uroprotection: a phase I study.
Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
4. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
[TBL] [Abstract][Full Text] [Related]
6. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Tolcher AW; Cowan KH; Noone MH; Denicoff AM; Kohler DR; Goldspiel BR; Barnes CS; McCabe M; Gossard MR; Zujewski J; O'Shaughnessy JA
J Clin Oncol; 1996 Jan; 14(1):95-102. PubMed ID: 8558227
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
[TBL] [Abstract][Full Text] [Related]
9. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
10. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Sørensen P; Pfeiffer P; Bertelsen K
Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue.
Shea TC; Storniolo AM; Mason JR; Newton B; Mullen M; Taetle R; Green MR
Semin Oncol; 1992 Feb; 19(1 Suppl 2):139-44. PubMed ID: 1411625
[TBL] [Abstract][Full Text] [Related]
15. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Skubitz KM; Hamdan H; Thompson RC
Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
17. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
18. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of cyclophosphamide (NSC 26271) by 72-hour continuous intravenous infusion.
Bedikian AY; Bodey GP
Am J Clin Oncol; 1983 Jun; 6(3):365-8. PubMed ID: 6846253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
